ClinicalTrials.gg
CompletedNCT05247879Updated Mar 25, 2024

Clinical Effectiveness and Safety of a Novel Oral Rehydration Solution

An interventional study of Glucose containing Oral Rehydration Solution (ORS) and Sugar free - amino acid and electrolyte ORS in Gastroenteritis Acute, sponsored by Mead Johnson Nutrition. Completed at 4 sites in Thailand. Open to participants aged 1 Year to 5 Years. Per ClinicalTrials.gov, last updated 2024-03-25.

Sponsored by Mead Johnson Nutrition (part of Reckitt) · Not applicable, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
1 Year to 5 Years
Sex
All
01

Study summary

This is a randomised, controlled, open-label study to determine the clinical effectiveness and safety of a novel ORS compared with a commercial ORS in children 1 to 5 years of age attending emergency departments with gastroenteritis.

02

Conditions studied

  • Gastroenteritis Acute

Browse trials for

03

In context

Gastroenteritis

237 studies on the registry are indexed under Gastroenteritis; 16 are open to participants now.

This study's enrollment of 60 is below the median of 136 across 164 interventional studies indexed under Gastroenteritis.

Browse Gastroenteritis studies →

Lead sponsor

Mead Johnson Nutrition is the lead sponsor of 58 studies on the registry; 1 is open to participants now.

First submitted after Mead Johnson Nutrition became part of Reckitt.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 to 5 years of age, inclusive at randomization
  • Hospitalized with mild to moderate dehydration due to ongoing diarrhea
  • Signed obtained for child's participation in the study

Exclusion criteria

Exclusion Criteria:

  • Severe dehydration and/or use of IV fluids for current hospitalization
  • Experiencing bloody diarrhea or diarrhea due to Cholera, Dysentery, persistent/chronic diarrhea, diarrhea with severe malnutrition, diarrhea associated with recent antibiotic use
  • In the opinion of the Investigator, not suitable for treatment with ORS
  • Have any underlying disease or disorder that may, in the opinion of the Investigator, affect the results of the study if they were enrolled (includes, but is not limited to, gastrointestinal disorders such as Crohn's disease or other inflammatory bowel disease or congenital malabsorption disorders)
  • Cause of the dehydration is something other than diarrhea
  • Known to be allergic to any of the components of the ORS
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Commercial reduced-osmolarity oral rehydration solution (ORS

    Dietary Supplement: Glucose containing Oral Rehydration Solution (ORS)

  • Experimental
    VS011, new children's ORS, a sugar-free blend of amino acids and electrolytes

    Dietary Supplement: Sugar free - amino acid and electrolyte ORS

Interventions

  • Dietary supplementGlucose containing Oral Rehydration Solution (ORS)

    Oral rehydration solution

  • Dietary supplementSugar free - amino acid and electrolyte ORS

    Glucose free oral rehydration solution

06

What researchers measure

Primary outcomes

  1. Clinically assessed adequate rehydration based on clinical judgement of change in or absence of presenting symptoms from baseline (i.e. heart rate, urine output, etc.)

    Assess change in clinical hydration status from presenting baseline status

    Time frame: every 4 hours up to 24 hours or hospital discharge, whichever occurs first

Secondary outcomes

  1. Clinical Assessment of patient's hydration status based on presenting symptoms (i.e. heart rate, urine output, etc.)

    5 point scale, 1(no discomfort) minimum, 5 (severe discomfort) maximum

    Time frame: Baseline

  2. Study ORS intake (units)

    Time frame: Every 4 hours up to 24 hours or hospital discharge, whichever occurs first

  3. Use of IV fluids

    Time frame: up to 24 hours or hospital discharge, whichever occurs first

  4. Weight

    kg

    Time frame: Every 4 hours up to 24 h or at hospital discharge, whichever occurs first

  5. Participant comfort questionaire

    Time frame: baseline and 24 hours or hospital discharge, whichever occurs first

  6. Parent satisfaction questionnaire

    Time frame: baseline and 24 hours or hospital discharge, whichever occurs first

  7. Frequency of vomiting

    Time frame: every 4 hours up to 24 hours or hospital discharge, whichever occurs first

  8. Frequency episodes of urination

    Time frame: every 4 hours up to 24 hours or hospital discharge, whichever occurs first

  9. Frequency of liquid/watery stool

    Time frame: every 4 hours up to 24 hours or hospital discharge, whichever occurs first

  10. Time to resolution of liquid/water stool

    Time frame: up to 24 hours or hospital discharge, whichever comes first

  11. Stool for bacterial pathogen culture and viral antigens

    Time frame: up to 24 hours or hospital discharge, whichever comes first

  12. Time ready for discharge

    Time frame: At discharge or 48 hours whichever occurs first

  13. Medically confirmed adverse events collected throughout the study period

    Time frame: 0 hours through 7 days post discharge

  14. Record patient use of antibiotics during hospitalization

    Time frame: up to 24 hours or hospital discharge, whichever comes first

07

Study locations

4 sites
  • Ramathibodi Hospital
    Bangkok, Thailand
  • Siriraj Hospital
    Bangkok, Thailand
  • Maharaj Nakorn Chiang Mai Hospital
    Chiang Mai, Thailand
  • Naresuan University Hospital
    Phitsanulok, Thailand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Sep 2023, 14 months.

Of 17 interventional studies with no phase under Gastroenteritis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 22. This study's 14 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2022
First posted
Feb 21, 2022
StartActual
Jun 30, 2022
Primary completionActual
Sep 20, 2023
CompletionActual
Jan 18, 2024
Last update
Mar 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05247879
Responsible party
Sponsor
First posted
Feb 21, 2022
Start date
Jun 30, 2022
Primary completion
Sep 20, 2023
Completion
Jan 18, 2024
Last update
Mar 25, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion